Ghulam Aziz, MD
Pulmonary Disease · East Liverpool, OHNPI 1366443343
Payments from drug & device makers
Across 341 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$820
- AstraZeneca$717
- GSK$642
- Harmony Biosciences LLC$560
- Jazz Pharmaceuticals Inc.$409
- Amgen$379
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,79785%
- Education$87915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 40 | $820 |
| AstraZeneca | 39 | $717 |
| GSK | 89 | $642 |
| Harmony Biosciences LLC | 30 | $560 |
| Jazz Pharmaceuticals Inc. | 12 | $409 |
| Amgen | 27 | $379 |
| Regeneron Healthcare Solutions, Inc. | 20 | $377 |
| Sanofi-aventis U.S. LLC | 3 | $252 |
| Boehringer Ingelheim | 14 | $251 |
| Grifols USA, LLC | 20 | $237 |
| Axsome Therapeutics, Inc. | 8 | $176 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $167 |
| Resmed Corp | 2 | $85 |
| Genentech USA, Inc. | 4 | $77 |
| United Therapeutics Corporation | 3 | $70 |
| Viatris Specialty LLC | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Lilly USA, LLC | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Insmed, Inc. | 2 | $36 |
| Verona Pharma, Inc. | 2 | $32 |
| Itamar Medical Inc | 1 | $30 |
| AbbVie | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Baxter Healthcare | 1 | $20 |
| Gilead | 1 | $20 |
| Boston Scientific | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
How this compares
$5,676 in reported general payments places this provider in the 65th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 67 | $942,894 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 33 | $311,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 351 | $259,295 |
| Spiriva RespimatTiotropium Bromide | 375 | $240,674 |
| Breo ElliptaFluticasone/Vilanterol | 390 | $202,359 |
| WakixPitolisant Hcl | 11 | $174,827 |
| Fasenra PenBenralizumab | 23 | $134,358 |
| Dupixent PenDupilumab | 28 | $113,046 |
| NucalaMepolizumab | 25 | $88,874 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 159 | $83,290 |
| SymbicortBudesonide/Formoterol Fumarate | 269 | $81,342 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $67,221 |
| FasenraBenralizumab | 11 | $66,857 |
| Incruse ElliptaUmeclidinium Bromide | 166 | $66,417 |
| Arnuity ElliptaFluticasone Furoate | 178 | $55,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $251 | $1,251,244547 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $642 | $756,2331,269 claims |
| Grifols USA, LLCProlastin C | $237 | $311,53333 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Fasenra, Bevespi Aerosphere | $717 | $233,744383 claims |
| Harmony Biosciences LLCWakix | $560 | $174,82711 claims |
| Axsome Therapeutics, Inc.Sunosi | $176 | $11,69815 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $51 | $7,68622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in East Liverpool
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.